This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Sanofi's Gene Therapy for Eye Disease Gets FDA's Fast Track Tag
by Zacks Equity Research
SNY's SAR446597, a one-time intravitreal gene therapy, secures FDA fast track tag for geographic atrophy due to age-related macular degeneration.
SNYPositive Net Change APLSNegative Net Change ARVNPositive Net Change AKRONegative Net Change
pharmaceuticals
JNJ Begins Drug Sector Q2 Earnings With a Beat & Guidance Raise
by Zacks Equity Research
JNJ tops second-quarter estimates and raises 2025 guidance as Innovative Medicines outperforms and MedTech gains momentum.
JNJNegative Net Change AMGNNegative Net Change TEVAPositive Net Change KVUENegative Net Change
pharmaceuticals
Strong Q2 Earnings, Cooling PPI Lead Pre-Markets Higher
by Mark Vickery
Headline PPI for June, month over month, reached 0.0% -- lower than the +0.2% expected and 30 bps below May.
GSPositive Net Change BACNegative Net Change MSPositive Net Change JNJNegative Net Change
banking earnings inflation pharmaceuticals
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
by Ahan Chakraborty
RXRX is scaling its AI-driven drug discovery technology through billion-dollar pharma deals and strategic tech alliances.
SDGRPositive Net Change RLAYNegative Net Change RXRXNo Net Change
artificial-intelligence biotechnology biotechs medical pharmaceuticals
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
by Kinjel Shah
Innovation is at its peak in the Zacks Medical-Drugs industry. CPRX, ZVRA, TBPH, ALDX and LRMR may prove to be good additions to one's portfolio.
CPRXNegative Net Change TBPHNegative Net Change ALDXPositive Net Change LRMRPositive Net Change ZVRANegative Net Change
pharmaceuticals
Will Increased Expenses Affect Bristol Myers' Performance?
by Ekta Bagri
BMY inks $3.5B bispecific antibody deal with BioNTech as top-line pressures and bottom-line risks mount.
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change BNTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
How Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?
by Sundeep Ganoria
ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.
AZNNegative Net Change PFENegative Net Change MRKNegative Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
BAYRY Skyrockets 62.9% YTD: Should You Buy or Sell the Stock?
by Zacks Equity Research
Bayer's shares are up 62.9% YTD as new drug approvals and a streamlined model fuel a sharp pharma turnaround.
REGNNegative Net Change JNJNegative Net Change BAYRYPositive Net Change
biotechnology medical pharmaceuticals
3 Medical Stocks to Watch as Q2 Earnings Approach: ABT, JNJ, NVS
by Shaun Pruitt
The broader market's historic rebound may make it necessary to consider some defensive positions in the portfolio, and these medical stocks fit the bill ahead of their Q2 reports.
ABTNegative Net Change NVSNegative Net Change JNJNegative Net Change
dividend-investing dividends earnings inflation investing large-cap medical medical-devices pharmaceuticals
Merck Starts Phase III Studies on Once-Monthly Pill for HIV Prevention
by Zacks Equity Research
MRK launches Phase III trials for its once-monthly HIV prevention pill MK-8527, aiming to rival Gilead's daily PrEP options.
GSKNegative Net Change MRKNegative Net Change GILDPositive Net Change
biotechs medical pharmaceuticals
The Zacks Analyst Blog Highlights Lilly, Netflix, GE Aerospace, Willis Lease and Flanigan's Enterprises
by Zacks Equity Research
LLY, NFLX, and GE lead this week???s top research picks as strong demand, growth strategies, and sector tailwinds fuel performance.
GENegative Net Change NFLXPositive Net Change LLYPositive Net Change WLFCNegative Net Change BDLNegative Net Change
aerospace consumer-discretionary pharmaceuticals restaurants transportation
Will Key Drugs Maintain Momentum for Novartis in Q2 Earnings?
by Zacks Equity Research
Strong sales of Entresto, Kisqali, Kesimpta, Leqvio and Scemblix have likely benefited NVS' Q2 performance and offset the impact of generics.
NVSNegative Net Change GILDPositive Net Change BAYRYPositive Net Change EXELNegative Net Change
biotechnology earnings medical pharmaceuticals
SLP's Q3 Earnings Top, Sales Up Y/Y, Stock Gains Despite Lowered View
by Zacks Equity Research
Simulation Plus' fiscal Q3 2025 earnings surge 67% on Pro-ficiency gains, but a cut in 2025 outlook shows hurdles in biosimulation and services.
FASTNegative Net Change SLPPositive Net Change BBNegative Net Change LEVINegative Net Change
earnings emerging-markets pharmaceuticals tech-stocks
How Will Pfizer's Oncology Drugs Perform in Q2 Earnings?
by Sundeep Ganoria
PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.
AZNNegative Net Change PFENegative Net Change MRKNegative Net Change
biotechs earnings medical pharmaceuticals
Here's How to Play AbbVie Stock as it Reaches Golden Cross
by Kinjel Shah
ABBV hits a bullish golden cross as Skyrizi and Rinvoq drive growth, offsetting Humira losses and aesthetic headwinds.
NVONegative Net Change LLYPositive Net Change ABBVNegative Net Change
pharmaceuticals
Novo Nordisk Plunges 20% YTD: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.
NVONegative Net Change LLYPositive Net Change AMGNNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
AstraZeneca Meets All Key Goals in Phase III Hypertension Study
by Zacks Equity Research
AZN hits all endpoints in phase III study for baxdrostat, a first-in-class treatment targeting hard-to-manage hypertension.
AZNNegative Net Change BAYRYPositive Net Change AGENNegative Net Change VRNANo Net Change
biotechnology biotechs medical pharmaceuticals
Ultragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIA
by Zacks Equity Research
RARE faces regulatory setback as FDA issues a CRL for UX111, delaying approval of the MPS IIIA gene therapy until 2026.
BAYRYPositive Net Change AGENNegative Net Change RARENegative Net Change VRNANo Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
Top Research Reports for Eli Lilly, Netflix & GE Aerospace
by Mark Vickery
LLY, NFLX, and GE lead today's top stock picks, with strong growth drivers but face headwinds from pricing, rivals, and costs.
BAPositive Net Change GENegative Net Change BXPositive Net Change CVXPositive Net Change NFLXPositive Net Change LLYPositive Net Change WLFCNegative Net Change BDLNegative Net Change
aerospace consumer-discretionary pharmaceuticals restaurants transportation
The Zacks Analyst Blog Highlights Microsoft, Alibaba Group, Merck, Monarch Cement and Team
by Zacks Equity Research
MSFT, BABA, and MRK headline today's top analyst picks, with AI, global e-commerce, and oncology driving mixed growth stories.
MSFTPositive Net Change MRKNegative Net Change TISIPositive Net Change BABAPositive Net Change MCEMPositive Net Change
business-services computers construction pharmaceuticals retail
MRK's Buyout Spree to Broaden Product Portfolio: Can it Aid Growth?
by Kanishka Das
Merck's impending Verona buyout and recent biotech deals aim to expand its pipeline and cut reliance on Keytruda sales.
SNYPositive Net Change MRKNegative Net Change LLYPositive Net Change VRNANo Net Change
pharmaceuticals
FDA Accepts GSK Filing for Expanded Use of RSV Shot in Younger Adults
by Zacks Equity Research
FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.
GSKNegative Net Change PFENegative Net Change MRNANegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Bayer Gets FDA Nod for Label Expansion of Kerendia in Heart Failure
by Zacks Equity Research
BAYRY wins FDA nod to expand Kerendia's label, making it the only approved non-steroidal MR antagonist for two major conditions.
NVSNegative Net Change JNJNegative Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Should J&J Stock Be in Your Portfolio Ahead of Q2 Earnings?
by Kinjel Shah
JNJ eyes Q2 growth with strong drug sales and new launches, but Stelara biosimilars and MedTech headwinds loom.
JNJNegative Net Change AMGNNegative Net Change KVUENegative Net Change
pharmaceuticals
Top Analyst Reports for Microsoft, Alibaba & Merck
by Mark Vickery
MSFT, BABA, and MRK lead today's top analyst picks, with AI, e-commerce, and cancer drug strategies in sharp focus.
MSFTPositive Net Change MRKNegative Net Change IBKRPositive Net Change BCENegative Net Change MPCPositive Net Change TISIPositive Net Change BABAPositive Net Change MCEMPositive Net Change
business-services computers construction pharmaceuticals retail